Voyager Therapeutics Inc
NASDAQ:VYGR

Watchlist Manager
Voyager Therapeutics Inc Logo
Voyager Therapeutics Inc
NASDAQ:VYGR
Watchlist
Price: 5.655 USD 4.14% Market Closed
Market Cap: 308.4m USD
Have any thoughts about
Voyager Therapeutics Inc?
Write Note

Intrinsic Value

VYGR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one VYGR stock under the Base Case scenario is 4.314 USD. Compared to the current market price of 5.655 USD, Voyager Therapeutics Inc is Overvalued by 24%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VYGR Intrinsic Value
4.314 USD
Overvaluation 24%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Voyager Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for VYGR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about VYGR?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Voyager Therapeutics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Voyager Therapeutics Inc

Provide an overview of the primary business activities
of Voyager Therapeutics Inc.

What unique competitive advantages
does Voyager Therapeutics Inc hold over its rivals?

What risks and challenges
does Voyager Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Voyager Therapeutics Inc recently?

Summarize the latest earnings call
of Voyager Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Voyager Therapeutics Inc.

Provide P/S
for Voyager Therapeutics Inc.

Provide P/E
for Voyager Therapeutics Inc.

Provide P/OCF
for Voyager Therapeutics Inc.

Provide P/FCFE
for Voyager Therapeutics Inc.

Provide P/B
for Voyager Therapeutics Inc.

Provide EV/S
for Voyager Therapeutics Inc.

Provide EV/GP
for Voyager Therapeutics Inc.

Provide EV/EBITDA
for Voyager Therapeutics Inc.

Provide EV/EBIT
for Voyager Therapeutics Inc.

Provide EV/OCF
for Voyager Therapeutics Inc.

Provide EV/FCFF
for Voyager Therapeutics Inc.

Provide EV/IC
for Voyager Therapeutics Inc.

Show me price targets
for Voyager Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Voyager Therapeutics Inc?

How accurate were the past Revenue estimates
for Voyager Therapeutics Inc?

What are the Net Income projections
for Voyager Therapeutics Inc?

How accurate were the past Net Income estimates
for Voyager Therapeutics Inc?

What are the EPS projections
for Voyager Therapeutics Inc?

How accurate were the past EPS estimates
for Voyager Therapeutics Inc?

What are the EBIT projections
for Voyager Therapeutics Inc?

How accurate were the past EBIT estimates
for Voyager Therapeutics Inc?

Compare the revenue forecasts
for Voyager Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Voyager Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Voyager Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Voyager Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Voyager Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Voyager Therapeutics Inc with its peers.

Analyze the financial leverage
of Voyager Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Voyager Therapeutics Inc.

Provide ROE
for Voyager Therapeutics Inc.

Provide ROA
for Voyager Therapeutics Inc.

Provide ROIC
for Voyager Therapeutics Inc.

Provide ROCE
for Voyager Therapeutics Inc.

Provide Gross Margin
for Voyager Therapeutics Inc.

Provide Operating Margin
for Voyager Therapeutics Inc.

Provide Net Margin
for Voyager Therapeutics Inc.

Provide FCF Margin
for Voyager Therapeutics Inc.

Show all solvency ratios
for Voyager Therapeutics Inc.

Provide D/E Ratio
for Voyager Therapeutics Inc.

Provide D/A Ratio
for Voyager Therapeutics Inc.

Provide Interest Coverage Ratio
for Voyager Therapeutics Inc.

Provide Altman Z-Score Ratio
for Voyager Therapeutics Inc.

Provide Quick Ratio
for Voyager Therapeutics Inc.

Provide Current Ratio
for Voyager Therapeutics Inc.

Provide Cash Ratio
for Voyager Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Voyager Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Voyager Therapeutics Inc?

What is the current Free Cash Flow
of Voyager Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Voyager Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Voyager Therapeutics Inc

Current Assets 373.4m
Cash & Short-Term Investments 345.4m
Receivables 19.7m
Other Current Assets 8.4m
Non-Current Assets 52.6m
PP&E 49.7m
Other Non-Current Assets 2.9m
Current Liabilities 44.2m
Accounts Payable 3.2m
Accrued Liabilities 18.4m
Other Current Liabilities 22.6m
Non-Current Liabilities 51.5m
Other Non-Current Liabilities 51.5m
Efficiency

Earnings Waterfall
Voyager Therapeutics Inc

Revenue
163.8m USD
Operating Expenses
-151.9m USD
Operating Income
11.9m USD
Other Expenses
14m USD
Net Income
25.9m USD

Free Cash Flow Analysis
Voyager Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

VYGR Profitability Score
Profitability Due Diligence

Voyager Therapeutics Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
ROE is Increasing
ROIC is Increasing
Positive ROIC
39/100
Profitability
Score

Voyager Therapeutics Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

VYGR Solvency Score
Solvency Due Diligence

Voyager Therapeutics Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
66/100
Solvency
Score

Voyager Therapeutics Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VYGR Price Targets Summary
Voyager Therapeutics Inc

Wall Street analysts forecast VYGR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VYGR is 17.567 USD with a low forecast of 7.07 USD and a high forecast of 31.5 USD.

Lowest
Price Target
7.07 USD
25% Upside
Average
Price Target
17.567 USD
211% Upside
Highest
Price Target
31.5 USD
457% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for VYGR?

Click here to dive deeper.

Dividends

Voyager Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for VYGR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

VYGR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

VYGR News

Profile

Voyager Therapeutics Inc Logo
Voyager Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

308.4m USD

Dividend Yield

0%

Description

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 101 full-time employees. The company went IPO on 2015-11-11. Its gene therapy platforms enable it to engineer, optimize, manufacture, and deliver its adeno-associated virus (AAV)-based gene therapies. The company is identifying AAV capsids, the outer viral protein shells that enclose genetic material of a virus payload. The company has developed a AAV capsid discovery platform, Tropism Redirection of AAV by Cell Type-Specific Expression of RNA (TRACER) to facilitate the selection of AAV capsids with blood brain barrier (BBB) crossing and cell-specific transduction properties for therapeutic applications. Its gene therapy programs include treatment programs for Huntington's disease, monogenic amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and various diseases linked to GBA1 mutations, including Parkinson's disease, Lewy body dementia and Gaucher's disease. The company also focuses on tauopathies and indications in neuro-oncology.

Contact

MASSACHUSETTS
Cambridge
75 Sidney St
+18572595340.0
www.voyagertherapeutics.com

IPO

2015-11-11

Employees

101

Officers

President, CEO & Director
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
COO & Acting Chief Business Officer
Ms. Robin Swartz
Chief Legal Officer
Ms. Jacquelyn Fahey Sandell Esq., J.D.
Founder
Dr. Mark A. Kay M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Phillip D. Zamore Ph.D.
Chief Financial Officer
Dr. Nathan D. Jorgensen M.B.A., Ph.D.
Show More
Chief Scientific Officer
Mr. Todd Carter Ph.D.
Chief Human Resources Officer
Ms. Michelle Quinn Smith
Show Less

See Also

Discover More
What is the Intrinsic Value of one VYGR stock?

The intrinsic value of one VYGR stock under the Base Case scenario is 4.314 USD.

Is VYGR stock undervalued or overvalued?

Compared to the current market price of 5.655 USD, Voyager Therapeutics Inc is Overvalued by 24%.

Back to Top